Eterna Therapeutics Gross Profit

Eterna Therapeutics (ERNA) currently reports a gross profit of $-160K as of June 2026. That compares with $360K in the prior-year period — down 143.1% year over year. That is below the Telecommunications sector average of $610B. Use the charts on this page to explore Eterna Therapeutics's gross profit history and peer comparisons.

Eterna Therapeutics's gross profit decreased from $360K to $-160K — a 143.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eterna Therapeutics's gross profit of $-160K is lower than the Telecommunications sector average of $610B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Eterna Therapeutics reported $-160K in gross profit as of June 2026. That compares with $360K in the prior-year period — down 143.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-160K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Telecommunications average is $610B. From there, open related valuation or income-statement pages for Eterna Therapeutics, and consider following ERNA for alerts when major investors trade the stock.